Adjuvant effect of Ubenimex on a DNA vaccine for HIV-1

Clinical and Experimental Immunology

Volumn 111, Issue 1, 1998, Pages 30-35

  Sasaki, S ^a   Fukushima, J ^a   Hamajima, K ^a   Ishii, N ^a   Tsuji, T ^a   Xin, K Q ^a   Mohri, H ^a   Okuda, K ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

DNA; HIV; Ubenimex; Vaccine

Indexed keywords

BESTATIN; DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HELPER CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOGLOBULIN PRODUCTION; IMMUNOMODULATION; INTRAMUSCULAR DRUG ADMINISTRATION; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIRUS GENE;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; HIV INFECTIONS; HUMANS; INJECTIONS, INTRAMUSCULAR; LEUCINE; MICE; MICE, INBRED BALB C; VACCINES, DNA;

EID: 0031905722     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1998.00466.x     Document Type: Article

References (36)

1. Ulmer JB, Donnelly JJ, Parker SE et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259:1745-9.
2. Fyna EF, Webster RG, Fuller DH et al. DNA vaccines - protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci USA 1993; 90:11478-82.
3. Xiang ZQ, Spitalnik SL, Cheng J et al. Immune response to nucleic acid vaccine to rabies virus. Virology 1995; 209:269-79.
4. Davis HL, McCluskie MJ, Gerin JL et al. DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proc Natl Acad Sci USA 1996; 93:7213-8.
5. Okuda K, Bukawa H, Hamajima K et al. Induction of potent humoral and cell-mediated immune responses following direct injection of DNA encoding the HIV type 1 env and rev gene products. AIDS Res Hum Retroviruses 1995; 11:933-43.
6. Lu S, Santoro JC, Fuller DH et al. Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice. Virology 1995; 209:147-54.
7. Boyer JD, Ligen KE, Wang B et al. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat Med 1997; 3:526-32.
8. Hassett DE, Whitton JL. DNA immunization. Trend Microbiol 1996; 4:307-12.
9. Davis HL, Michel ML, Whalen RG. Use of plasmid DNA for direct gene transfer and immunization. In: Liu MA, Hilleman MR, Kurth R, eds. DNA vaccine-new era in vaccinology. New York: NY Acad Sci 1995; 772:21-29.
10. Golding B, Scott DE. Vaccine strategies: targetting helper T cell responses. In: Williams JC, Goldenthal KL, Burns DA, Lewis BJJ, eds. Combined vaccine and simultaneous administration-current issues and perspectives. New York: NY Acad Sci 1995; 754:126-37.
11. Mossmann TR, Coffman RL. Heterogeneity of cytokine secretion patterns and function of helper T cells. Adv Immunol 1989; 46:111-6.
12. Ishizuka ST, Piacente P, Silva J et al. IgG subtype is correlated with efficacy of passive protection and effector function of anti-herpes simplex virus glycoprotein D monoclonal antibodies. J Infect Dis 1995; 172:1108-11.
13. + Th1 clones with both cytotoxic and helper activity mediate protective humoral immunity against a lethal poliovirus infection in transgenic mice expressing the human poliovirus receptor. J Exp Med 1995; 181:1285-92.
14. Maraskovsky E, Chen W-F, Shortman K. IL-2 and IFN-γ are two necessary lymphokines in the development of cytolytic T cells. J Immunol 1989; 143:1210-4.
15. Ulmer JB, Donnelly JJ, Liu MA. DNA vaccines promising: A new approach to inducing protective immunity. ASM News 1996; 62: 476-9.
16. Umezawa H, Aoyagi T, Suda H et al. Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes. J Antibiot 1976; 29:97-104.
17. Urabe A, Mutoh Y, Mizoguchi H et al. Ubenimex in the treatment of acute nonlymphocytic leukemia in adults. Ann Hematol 1993; 67:63-66.
18. Shibuya K, Hayashi E, Abe F et al. Enhancement of interleukin 1 and interleukin 2 releases by ubenimex. J Antibiot 1987; 40:363-9.
19. Okamura S, Omori F, Haga K et al. Influence of bestatin on production of granulocyte-macrophage colony-stimulating factor from human peripheral blood mononuclear cells in vitro. Acta Oncologica 1990; 29:795-7.
20. Mathé G. Bestatin, an aminopeptidase inhibitor with a multi-pharmacological function. Biomed Pharmacother 1991; 45:49-54.
21. Ito K, Handa J, Irie Y. Toxicological studies on bestatin III - chronic toxicity test and recovery study in beagle dogs. Jpn J Antibiot 1983; 36:3053-93.
22. Malim MH, Hauber J, Fenrick R et al. Immunodeficiency virus rev transactivator modulates the expression of the viral regulatory genes. Nature 1988; 335:181-3.
23. Layton GT, Harris SJ, Gearing AJ et al. Induction of HIV-specific cytotoxic T lymphocytes in vivo with hybrid HIV-1 V3:Ty-virus-like particles. J Immunol 1993; 151:1097-107.
24. Takahashi H, Germain RN, Moss B et al. An immunodominant class I-restricted cytotoxic T lymphocyte determinant of human immunodeficiency virus type 1 induces CD4 II-restricted help for itself. J Exp Med 1990; 171:571-6.
25. Okuda K, Twining SS, David CS et al. Genetic control of immune response to sperm whale myoglobin in mice. II. T lymphocyte proliferative response to the synthetic antigenic sites. J Immunol 1979; 123:182-8.
26. Mosmann TR, Coffman RL. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7:145.
27. Talmadge JE, Lenz BF, Pennington R et al. Immunomodulatory and therapeutic properties of bestatin in mice. Cancer Res 1986; 46:4505-10.
28. Florentin I, Kiger N, Bruley-Rosset M et al. Effect of seven immunomodulators on different types of immune responses in mice. Human lymphocyte differentiation. Amsterdam: North Holland Biomedical Press, 1978: 299.
29. Watanabe A, Raz E, Kohsaka H et al. Induction of antibodies to a kappa V region by gene immunization. J Immunol 1993; 151:2871-6.
30. Tsuji T, Hamajima K, Fukushima J et al. Enhancement of cell-mediated immunity against HIV-1 induced by coinoculation of plasmid-encoded HIV-1 antigen with plasmid expressing IL-12. J Immunol 1997; 158:4008-14.
31. Ada GL, McElrath MJ. HIV type 1 vaccine-induced cytotoxic T cell responses: Potential role in vaccine efficacy. AIDS Res Hum Retroviruses 1997; 13:205-10.
32. Abe F, Hayashi M, Uchida M et al. Effect of Bestatin on syngenic tumor in mice. Gann 1984; 75:89-94.
33. Bourinbaiar AS, Lee HS, Krasinski K et al. Inhibitory effect of the oral immune response modifier, bestatin, on cell- mediated and cell-free HIV infection in vitro. Biomed Pharmacother 1994; 48:55-61.
34. Hording M, Gotzsche PC, Daih-Christensen L et al. Double-blind trial of bestatin in HIV-positive patients. Biomed Pharmacother 1990; 44:475-8.
35. Gupta RK, Siber GR. Adjuvants for human vaccines-current status, problems and future prospects. Vaccine 1995; 13:1263-76.
36. Powell MF, Newman MJ. Vaccine design: the subunit and adjuvant approach: New York: Plenum Press, 1995.